Pluri (PLUR) Income towards Parent Company (2010 - 2025)
Pluri (PLUR) posted quarterly Income towards Parent Company of -$6.9 million for Q4 2025, down 120.96% year-over-year from $32.8 million in Q4 2024, and down 12.07% quarter-over-quarter from -$6.1 million in Q3 2025.
Pluri (PLUR) Income towards Parent Company (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Income towards Parent Company for 16 consecutive years, with -$6.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Income towards Parent Company fell 120.96% year-over-year to -$6.9 million; the TTM figure through Dec 2025 stood at -$25.5 million (down 19.45% YoY), while the FY2025 annual figure was -$23.2 million, down 8.93% from the prior year.
- Income towards Parent Company retreated to -$6.9 million in Q4 2025 per PLUR's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $7.8 million in Q1 2023 and bottomed at -$14.6 million in Q2 2021.
- Historically, Income towards Parent Company has averaged -$5.5 million across 5 years, with a median of -$6.4 million in 2022.
- Annual changes were most pronounced in 2023 — Income towards Parent Company surged 176.76% — and 2024, when it plunged 221.67%.
- Pluri's Income towards Parent Company stood at -$11.2 million in 2021, then grew by 24.17% to -$8.5 million in 2022, then soared by 157.94% to $4.9 million in 2023, then tumbled by 163.4% to -$3.1 million in 2024, then plunged by 120.96% to -$6.9 million in 2025.
- Business Quant data shows PLUR's Income towards Parent Company at -$6.9 million in Q4 2025, -$6.1 million in Q3 2025, and -$6.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.87 Mn |
| Sep 30, 2025 | -6.13 Mn |
| Jun 30, 2025 | -6.85 Mn |
| Mar 31, 2025 | -5.61 Mn |
| Dec 31, 2024 | -3.11 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Jun 30, 2024 | -6.25 Mn |
| Mar 31, 2024 | -5.92 Mn |
| Dec 31, 2023 | 4.91 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 6.04 Mn |
| Mar 31, 2023 | 7.76 Mn |
| Dec 31, 2022 | -8.47 Mn |
| Sep 30, 2022 | -6.46 Mn |
| Jun 30, 2022 | -9.17 Mn |
| Mar 31, 2022 | -10.14 Mn |
| Dec 31, 2021 | -11.17 Mn |
| Sep 30, 2021 | -11.66 Mn |
| Jun 30, 2021 | -14.65 Mn |
| Mar 31, 2021 | -14.44 Mn |